We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
RITALIN LA methylphenidate hydrochloride 10mg capsules (Switzerland)
Section 19A approved medicine
RITALIN LA methylphenidate hydrochloride 10mg capsules (Switzerland)
Section 19A approval holder
Phero Pharma Pty Ltd ABN 96 673 730 231
Phone
02 9420 9199
Approved until
Status
Current
Medicines in short supply/unavailable
RITALIN LA methylphenidate hydrochloride 10 mg modified release capsule bottle - ARTG 160228
RUBIFEN LA methylphenidate hydrochloride 10 mg modified release capsules blister pack - ARTG 362233
RUBIFEN LA methylphenidate hydrochloride 10 mg modified release capsules blister pack - ARTG 362233
Indication(s)
Methylphenidate hydrochloride modified release capsules are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and children aged 6 years and over.
Images
